A clinical trial set to launch at the University of Colorado Cancer Center will test a therapy designed to fire the body’s natural defenses against a deadly blood cancer.
The target is acute lymphoblastic leukemia
(ALL), a cancer that strikes the lymphocytes, which are immature white blood cells in the bone marrow. It most often is treated with chemotherapy, drugs that target specific genetic mutations, and stem cell bone marrow transplants. Children have the greatest chance of surviving the disease. However, for some ALL patients the available treatments fail.